Synopsis
Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Amizepine
2. Carbamazepine Acetate
3. Carbamazepine Anhydrous
4. Carbamazepine Dihydrate
5. Carbamazepine Hydrochloride
6. Carbamazepine L-tartrate (4:1)
7. Carbamazepine Phosphate
8. Carbamazepine Sulfate (2:1)
9. Carbazepin
10. Epitol
11. Finlepsin
12. Neurotol
13. Tegretol
1. 298-46-4
2. Tegretol
3. Carbamazepen
4. Finlepsin
5. Biston
6. 5h-dibenzo[b,f]azepine-5-carboxamide
7. Equetro
8. Tegretal
9. 5h-dibenz[b,f]azepine-5-carboxamide
10. Carbazepine
11. Neurotol
12. Epitol
13. Timonil
14. Carbamezepine
15. Carbatrol
16. Karbamazepin
17. Stazepine
18. Telesmin
19. Lexin
20. Tegretol-xr
21. Benzo[b][1]benzazepine-11-carboxamide
22. Carbamazepin
23. Carbamazepinum
24. Teril
25. Geigy 32883
26. 5h-dibenz(b,f)azepine-5-carboxamide
27. Carbamazepina
28. Amizepin
29. Bipotrol
30. Carnexiv
31. Sirtal
32. 5-carbamyl-5h-dibenzo(b,f)azepine
33. 5-carbamoyl-5h-dibenzo(b,f)azepine
34. Calepsin
35. Carbamazepine Anhydrous
36. 5-carbamoyl-5h-dibenz(b,f)azepine
37. 5-carbamoyl-5h-dibenz[b,f]azepine
38. G-32883
39. G 32883
40. Karbelex
41. Neurotop
42. Nsc 169864
43. Mfcd00005073
44. Chebi:3387
45. Chembl108
46. Nsc-169864
47. Carbamazepine Extended Release
48. 5-carbamyldibenzo(b,f)azepine
49. Mls000069652
50. 5-carbamoyldibenzo(b,f)azepine
51. Cbz
52. Nsc169864
53. 33cm23913m
54. Ncgc00015234-11
55. Cas-298-46-4
56. Smr000058201
57. Stazepin
58. Dsstox_cid_2731
59. 2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,9,12,14-heptaene-2-carboxamide
60. Dsstox_rid_76704
61. Dsstox_gsid_22731
62. 5h-dibenzo[b,f]azepine-5-carboxamide;oxcarbazepine Impurity A
63. Carbelan
64. Tegretol Cr
65. Carbamazepinum [inn-latin]
66. Carbamazepina [inn-spanish]
67. Smr001227191
68. Hsdb 3019
69. Sr-01000000229
70. Carbatrol Extended-release
71. Einecs 206-062-7
72. Brn 1246090
73. Trimonil
74. Neurotop Retard
75. Unii-33cm23913m
76. Dibenzo[b,f]azepine-5-carboxamide
77. Tegretol (tn)
78. Prestwick_104
79. Equetro (tn)
80. Carbamazepine-[d2]
81. Carbamazepine, Powder
82. Opera_id_72
83. Spectrum_000096
84. Carbamazepine [usan:usp:inn:ban:jan]
85. Prestwick0_000052
86. Prestwick1_000052
87. Prestwick2_000052
88. Prestwick3_000052
89. Spectrum2_000125
90. Spectrum3_000325
91. Spectrum4_000262
92. Spectrum5_000936
93. Carbamazepine (carbatrol)
94. Lopac-c-4024
95. Chemdiv1_018966
96. Carbamazepine [mi]
97. Cbchromo1_000350
98. Epitope Id:174842
99. Iminostilbene-n-carboxamide
100. Carbamazepine [inn]
101. Carbamazepine [jan]
102. Carbamazepine [hsdb]
103. Carbamazepine [usan]
104. Carbamazepine-[13c,15n]
105. Lopac0_000292
106. Oprea1_790775
107. Schembl21639
108. Bspbio_000203
109. Bspbio_001929
110. Carbamazepine [vandf]
111. Kbiogr_000724
112. Kbioss_000516
113. Mls001055475
114. Mls001074172
115. Mls002548877
116. Bidd:gt0479
117. Carbamazepine [mart.]
118. Divk1c_000388
119. Divk1c_003750
120. Spectrum1500159
121. Spbio_000170
122. Spbio_002124
123. Carbamazepine [usp-rs]
124. Carbamazepine [who-dd]
125. Carbamazepine [who-ip]
126. Bpbio1_000225
127. Gtpl5339
128. Zinc4785
129. Dtxsid4022731
130. Schembl19838283
131. Hms501d10
132. Hms640o02
133. Kbio1_000388
134. Kbio2_000516
135. Kbio2_003084
136. Kbio2_005652
137. Kbio3_001149
138. Wln: T C676 Bnj Bvz
139. Carbamazepine (jp17/usp/inn)
140. Cbz;nsc 169864
141. Spd-417
142. Carbamazepine, Analytical Standard
143. Ninds_000388
144. Hms1568k05
145. Hms1920i17
146. Hms2090m07
147. Hms2091o19
148. Hms2095k05
149. Hms2233g16
150. Hms3039k09
151. Hms3259b21
152. Hms3260l06
153. Hms3372j13
154. Hms3657g03
155. Hms3712k05
156. Hms3747e03
157. Pharmakon1600-01500159
158. Carbamazepine [orange Book]
159. Act02606
160. Bcp21380
161. Hy-b0246
162. 5-carbomoyl-5h-dibenzo(b,f)azepine
163. Carbamazepine [ep Monograph]
164. Carbamazepine [usp Impurity]
165. Tox21_110104
166. Tox21_202273
167. Tox21_300195
168. Tox21_500292
169. Ac2074
170. Bdbm50003659
171. Carbamazepine [usp Monograph]
172. Ccg-38931
173. Nsc755920
174. S1693
175. Stk177357
176. Stl453548
177. 11-benzo[b][1]benzazepinecarboxamide
178. 5h-dibenz[b,f]azepine-5-carboxamine
179. Carbamazepine 1.0 Mg/ml In Methanol
180. Carbamazepinum [who-ip Latin]
181. Akos003235644
182. Akos025397243
183. Tox21_110104_1
184. Ac-9538
185. Db00564
186. Ks-5146
187. Lp00292
188. Nc00679
189. Nsc-755920
190. Sdccgsbi-0050280.p005
191. 5h-dibenz[ B, F]azepine-5-carboxamide
192. Carbamazepin 100 Microg/ml In Methanol
193. Cds1_002710
194. Idi1_000388
195. 5h-dibenzo[b,f]azepine-5-carboxamide #
196. Ncgc00015234-01
197. Ncgc00015234-02
198. Ncgc00015234-03
199. Ncgc00015234-04
200. Ncgc00015234-05
201. Ncgc00015234-06
202. Ncgc00015234-07
203. Ncgc00015234-08
204. Ncgc00015234-09
205. Ncgc00015234-10
206. Ncgc00015234-12
207. Ncgc00015234-13
208. Ncgc00015234-14
209. Ncgc00015234-15
210. Ncgc00015234-16
211. Ncgc00015234-18
212. Ncgc00015234-19
213. Ncgc00015234-33
214. Ncgc00023877-03
215. Ncgc00023877-04
216. Ncgc00023877-05
217. Ncgc00023877-06
218. Ncgc00023877-07
219. Ncgc00023877-08
220. Ncgc00253982-01
221. Ncgc00259822-01
222. Ncgc00260977-01
223. Bc166161
224. Sy002823
225. (z)-5h-dibenzo[b,f]azepine-5-carboxamide
226. Sbi-0050280.p004
227. 5h-dibenzo[b,f]azepine-5-carboximidic Acid
228. Db-047659
229. Dibenzo[b,f]azepine-5-carboxylic Acid Amide
230. Eu-0100292
231. Ft-0602927
232. Ft-0696814
233. Sw220141-1
234. Oxcarbazepine Impurity A [ep Impurity]
235. Bim-0050280.0001
236. C 4024
237. C06868
238. Carbamazepine, Meets Usp Testing Specifications
239. D00252
240. 5h-dibenz(b,f)azepine-5-carboxamide Maleic Acid
241. 5h-dibenz(b,f)azepine-5-carboxamide Oxalic Acid
242. Ab00051931-17
243. Ab00051931-18
244. Ab00051931_19
245. Ab00051931_20
246. A820074
247. Q410412
248. Carbamazepine Host Structure With Maleic Acid Removed
249. Carbamazepine Host Structure With Oxalic Acid Removed
250. Q-200792
251. Sr-01000000229-2
252. Sr-01000000229-4
253. Sr-01000000229-7
254. 5h-dibenz(b,f)azepine-5-carboxamide Dl-tartaric Acid
255. Brd-k71799949-001-06-7
256. F0348-2551
257. Z2199879032
258. Carbamazepine Host Structure With Dl-tartaric Acid Removed
259. Dibenzo[b,f]azepine-5-carboxylic Acid Amide(carbamazepine)
260. Carbamazepine Host Structure With 4-hydroxybenzoic Acid Removed
261. Carbamazepine, British Pharmacopoeia (bp) Reference Standard
262. Carbamazepine, European Pharmacopoeia (ep) Reference Standard
263. Carbamazepine, United States Pharmacopeia (usp) Reference Standard
264. Carbamazepine Solution, 1.0 Mg/ml In Methanol, Ampule Of 1 Ml, Certified Reference Material
265. Carbamazepine, Pharmaceutical Secondary Standard; Certified Reference Material
266. N6w
| Molecular Weight | 236.27 g/mol |
|---|---|
| Molecular Formula | C15H12N2O |
| XLogP3 | 2.5 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 1 |
| Rotatable Bond Count | 0 |
| Exact Mass | 236.094963011 g/mol |
| Monoisotopic Mass | 236.094963011 g/mol |
| Topological Polar Surface Area | 46.3 Ų |
| Heavy Atom Count | 18 |
| Formal Charge | 0 |
| Complexity | 326 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 14 | |
|---|---|
| Drug Name | Carbamazepine |
| PubMed Health | Carbamazepine (By mouth) |
| Drug Classes | Anticonvulsant, Neuropathic Pain Agent |
| Drug Label | Carbamazepine USP is an anticonvulsant and specific analgesic for trigeminal neuralgia, available for oral administration as chewable tablets of 100 mg and tablets of 200 mg. Its chemical name is 5H-dibenz[b,f]azepine-5-carboxamide, and its structura... |
| Active Ingredient | Carbamazepine |
| Dosage Form | Tablet, extended release; Tablet; Capsule, extended release; Tablet, chewable; Suspension |
| Route | oral; Oral |
| Strength | 300mg; 200mg; 100mg; 100mg/5ml; 400mg |
| Market Status | Tentative Approval; Prescription |
| Company | Wockhardt; Teva Pharms; Apotex; Teva Pharms Usa; Taro Pharm Inds; Taro; Torrent Pharms; Nostrum |
| 2 of 14 | |
|---|---|
| Drug Name | Carbatrol |
| PubMed Health | Carbamazepine (By mouth) |
| Drug Classes | Anticonvulsant, Neuropathic Pain Agent |
| Drug Label | CARBATROL* is an anticonvulsant and specific analgesic for trigeminal neuralgia, available for oral administration as 100 mg, 200 mg and 300 mg extended-release capsules of Carbamazepine, USP. Carbamazepine is a white to off-white powder, practically... |
| Active Ingredient | Carbamazepine |
| Dosage Form | Capsule, extended release |
| Route | Oral |
| Strength | 300mg; 200mg; 100mg |
| Market Status | Prescription |
| Company | Shire |
| 3 of 14 | |
|---|---|
| Drug Name | Epitol |
| PubMed Health | Carbamazepine (By mouth) |
| Drug Classes | Anticonvulsant, Neuropathic Pain Agent |
| Drug Label | Epitol, carbamazepine, USP, is an anticonvulsant and specific analgesic for trigeminal neuralgia, available for oral administration as tablets of 200 mg. Its chemical name is 5H-dibenz[b,f]azepine-5-carboxamide, and its structural formula is: C15H12N... |
| Active Ingredient | Carbamazepine |
| Dosage Form | Tablet; Tablet, chewable |
| Route | Oral |
| Strength | 200mg; 100mg |
| Market Status | Prescription |
| Company | Teva |
| 4 of 14 | |
|---|---|
| Drug Name | Equetro |
| PubMed Health | Carbamazepine (By mouth) |
| Drug Classes | Anticonvulsant, Neuropathic Pain Agent |
| Drug Label | EQUETRO (carbamazepine) is a mood stabilizer available for oral administration as 100 mg, 200 mg, and 300 mg extended-release capsules of carbamazepine, USP. Carbamazepine is a white to off-white powder, practically insoluble in water and soluble in... |
| Active Ingredient | Carbamazepine |
| Dosage Form | Capsule, extended release |
| Route | Oral |
| Strength | 300mg; 200mg; 100mg |
| Market Status | Prescription |
| Company | Validus Pharms |
| 5 of 14 | |
|---|---|
| Drug Name | Tegretol |
| Drug Label | Tegretol, carbamazepine USP, is an anticonvulsant and specific analgesic for trigeminal neuralgia, available for oral administration as chewable tablets of 100mg, tablets of 200mg, XR tablets of 100, 200, and 400mg, and as a suspension of 100... |
| Active Ingredient | Carbamazepine |
| Dosage Form | Tablet; Suspension; Tablet, chewable |
| Route | Oral |
| Strength | 200mg; 100mg/5ml; 100mg |
| Market Status | Prescription |
| Company | Novartis |
| 6 of 14 | |
|---|---|
| Drug Name | Tegretol-xr |
| Active Ingredient | Carbamazepine |
| Dosage Form | Tablet, extended release |
| Route | Oral |
| Strength | 200mg; 400mg; 100mg |
| Market Status | Prescription |
| Company | Novartis |
| 7 of 14 | |
|---|---|
| Drug Name | Teril |
| Active Ingredient | Carbamazepine |
| Dosage Form | Suspension |
| Route | Oral |
| Strength | 100mg/5ml |
| Market Status | Prescription |
| Company | Taro |
| 8 of 14 | |
|---|---|
| Drug Name | Carbamazepine |
| PubMed Health | Carbamazepine (By mouth) |
| Drug Classes | Anticonvulsant, Neuropathic Pain Agent |
| Drug Label | Carbamazepine USP is an anticonvulsant and specific analgesic for trigeminal neuralgia, available for oral administration as chewable tablets of 100 mg and tablets of 200 mg. Its chemical name is 5H-dibenz[b,f]azepine-5-carboxamide, and its structura... |
| Active Ingredient | Carbamazepine |
| Dosage Form | Tablet, extended release; Tablet; Capsule, extended release; Tablet, chewable; Suspension |
| Route | oral; Oral |
| Strength | 300mg; 200mg; 100mg; 100mg/5ml; 400mg |
| Market Status | Tentative Approval; Prescription |
| Company | Wockhardt; Teva Pharms; Apotex; Teva Pharms Usa; Taro Pharm Inds; Taro; Torrent Pharms; Nostrum |
| 9 of 14 | |
|---|---|
| Drug Name | Carbatrol |
| PubMed Health | Carbamazepine (By mouth) |
| Drug Classes | Anticonvulsant, Neuropathic Pain Agent |
| Drug Label | CARBATROL* is an anticonvulsant and specific analgesic for trigeminal neuralgia, available for oral administration as 100 mg, 200 mg and 300 mg extended-release capsules of Carbamazepine, USP. Carbamazepine is a white to off-white powder, practically... |
| Active Ingredient | Carbamazepine |
| Dosage Form | Capsule, extended release |
| Route | Oral |
| Strength | 300mg; 200mg; 100mg |
| Market Status | Prescription |
| Company | Shire |
| 10 of 14 | |
|---|---|
| Drug Name | Epitol |
| PubMed Health | Carbamazepine (By mouth) |
| Drug Classes | Anticonvulsant, Neuropathic Pain Agent |
| Drug Label | Epitol, carbamazepine, USP, is an anticonvulsant and specific analgesic for trigeminal neuralgia, available for oral administration as tablets of 200 mg. Its chemical name is 5H-dibenz[b,f]azepine-5-carboxamide, and its structural formula is: C15H12N... |
| Active Ingredient | Carbamazepine |
| Dosage Form | Tablet; Tablet, chewable |
| Route | Oral |
| Strength | 200mg; 100mg |
| Market Status | Prescription |
| Company | Teva |
| 11 of 14 | |
|---|---|
| Drug Name | Equetro |
| PubMed Health | Carbamazepine (By mouth) |
| Drug Classes | Anticonvulsant, Neuropathic Pain Agent |
| Drug Label | EQUETRO (carbamazepine) is a mood stabilizer available for oral administration as 100 mg, 200 mg, and 300 mg extended-release capsules of carbamazepine, USP. Carbamazepine is a white to off-white powder, practically insoluble in water and soluble in... |
| Active Ingredient | Carbamazepine |
| Dosage Form | Capsule, extended release |
| Route | Oral |
| Strength | 300mg; 200mg; 100mg |
| Market Status | Prescription |
| Company | Validus Pharms |
| 12 of 14 | |
|---|---|
| Drug Name | Tegretol |
| Drug Label | Tegretol, carbamazepine USP, is an anticonvulsant and specific analgesic for trigeminal neuralgia, available for oral administration as chewable tablets of 100mg, tablets of 200mg, XR tablets of 100, 200, and 400mg, and as a suspension of 100... |
| Active Ingredient | Carbamazepine |
| Dosage Form | Tablet; Suspension; Tablet, chewable |
| Route | Oral |
| Strength | 200mg; 100mg/5ml; 100mg |
| Market Status | Prescription |
| Company | Novartis |
| 13 of 14 | |
|---|---|
| Drug Name | Tegretol-xr |
| Active Ingredient | Carbamazepine |
| Dosage Form | Tablet, extended release |
| Route | Oral |
| Strength | 200mg; 400mg; 100mg |
| Market Status | Prescription |
| Company | Novartis |
| 14 of 14 | |
|---|---|
| Drug Name | Teril |
| Active Ingredient | Carbamazepine |
| Dosage Form | Suspension |
| Route | Oral |
| Strength | 100mg/5ml |
| Market Status | Prescription |
| Company | Taro |
Analgesics, Non-Narcotic; Anticonvulsants
National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)
Carbamazepine has been shown to be effective in certain psychiatric disorders including schizoaffective illness, resistant schizophrenia, and dyscontrol syndrome, associated with limbic system dysfunction. /NOT included in US or Canadian product labeling/
Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2007., p. 703
Carbamazepine is used for the detoxification of alcoholics. It has been found to be effective in rapidly relieving anxiety and distress of acute alcohol withdrawal and for such symptoms as seizures, hyperexcitability, and sleep disturbances. /NOT included in US product labeling/
Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2007., p. 703
Carbamazepine is used alone or with other agents such as clofibrate or chlorpropamide in the treatment of partial central diabetes insipidus. /NOT included in US or Canadian product labeling/
Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2007., p. 703
For more Therapeutic Uses (Complete) data for CARBAMAZEPINE (10 total), please visit the HSDB record page.
There have been a few cases of seizures and/or respiratory depression in neonates born to women receiving carbamazepine concomitantly with other anticonvulsant agents. A few cases of vomiting, diarrhea, and/or decreased feeding also have been reported in neonates born to women receiving carbamazepine; these symptoms may represent a neonatal withdrawal syndrome
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2007., p. 2223
Carbamazepine should not be used prophylactically during long periods of remission in trigeminal neuralgia.
Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2007., p. 703
Although carbamazepine has ... been reported to relieve dystonic attacks in children, reduce migraine attacks, and relieve intractable hiccups in some patients, its therapeutic efficacy in such cases has not been established.
Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2007., p. 703
Carbamazepine is not indicated for atypical or generalized absence seizures (petit mal) or myoclonic or atonic seizures.
Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2007., p. 703
For more Drug Warnings (Complete) data for CARBAMAZEPINE (30 total), please visit the HSDB record page.
Carbamazepine is indicated for the treatment of epilepsy and pain associated with true trigeminal neuralgia. In particular, carbamazepine has shown efficacy in treating mixed seizures, partial seizures with complex symptoms, and generalized tonic-clonic seizures. Carbamazepine is also indicated for the treatment of manic episodes and mixed manic-depressive episodes caused by bipolar I disorder. Some off-label, unapproved uses of carbamazepine include the treatment of alcohol withdrawal syndrome and restless leg syndrome.
FDA Label
**General effects** Carbamazepine treats seizures and the symptoms of trigeminal neuralgia by inhibiting sodium channels. In bipolar 1 disorder, carbamazepine has been found to decrease mania symptoms in a clinically significant manner according to the Young Mania Rating Scale (YMRS). Carbamazepine has a narrow therapeutic index. **A note on genetic variation and carbamazepine use** In studies of Han Chinese ancestry patients, a pronounced association between the HLA-B*1502 genotype and Steven Johnson syndrome and/or toxic epidermal necrolysis (SJS/TEN) resulting from carbamazepine use was observed.
Antimanic Agents
Agents that are used to treat bipolar disorders or mania associated with other affective disorders. (See all compounds classified as Antimanic Agents.)
Anticonvulsants
Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)
Cytochrome P-450 CYP3A Inducers
Drugs and compounds that induce the synthesis of CYTOCHROME P-450 CYP3A. (See all compounds classified as Cytochrome P-450 CYP3A Inducers.)
Analgesics, Non-Narcotic
A subclass of analgesic agents that typically do not bind to OPIOID RECEPTORS and are not addictive. Many non-narcotic analgesics are offered as NONPRESCRIPTION DRUGS. (See all compounds classified as Analgesics, Non-Narcotic.)
Sodium Channel Blockers
A class of drugs that act by inhibition of sodium influx through cell membranes. Blockade of sodium channels slows the rate and amplitude of initial rapid depolarization, reduces cell excitability, and reduces conduction velocity. (See all compounds classified as Sodium Channel Blockers.)
N03AF01
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
N03AF01
S66 | EAWAGTPS | Parent-Transformation Product Pairs from Eawag | DOI:10.5281/zenodo.3754448
N03AF01
S66 | EAWAGTPS | Parent-Transformation Product Pairs from Eawag | DOI:10.5281/zenodo.3754448
N03AF01
S66 | EAWAGTPS | Parent-Transformation Product Pairs from Eawag | DOI:10.5281/zenodo.3754448
N - Nervous system
N03 - Antiepileptics
N03A - Antiepileptics
N03AF - Carboxamide derivatives
N03AF01 - Carbamazepine
Absorption
The bioavailability of carbamazepine is in the range of 75-85% of an ingested dose. After one 200 mg oral extended-release dose of carbamazepine in a pharmacokinetic study, the Cmax carbamazepine was measured to be 1.9 0.3 mcg/mL. The Tmax was 19 7 hours. After several doses of 800 mg every 12 hours, the peak concentrations of carbamazepine were measured to be 11.0 2.5 mcg/mL. The Tmax was reduced to 5.9 1.8 hours. Extended-release carbamazepine demonstrated linear pharmacokinetics over a range of 200800 mg. **Effect of food on absorption** A meal containing high-fat content increased the rate of absorption of one 400 mg dose but not the AUC of carbamazepine. The elimination half-life remained unchanged between fed and fasting state. The pharmacokinetics of an extended-release carbamazepine dose was demonstrated to be similar when administered in the fasted state or with food. Based on these findings, food intake is unlikely to exert significant effects on carbamazepine absorption.
Route of Elimination
After an oral dose of radiolabeled carbamazepine, 72% of the administered radioactive dose was detected in the urine and the remainder of the ingested dose was found in the feces. Carbamazepine is mainly excreted as hydroxylated and conjugated metabolites, and minimal amounts of unchanged drug.
Volume of Distribution
The volume of distribution of carbamazepine was found to be 1.0 L/kg in one pharmacokinetic study. Another study indicates that the volume of distribution of carbamazepine ranges between 0.7 to 1.4 L/kg.. Carbamazepine crosses the placenta, and higher concentrations of this drug are found in the liver and kidney as opposed to lung and brain tissue. Carbamazepine crosses variably through the blood-brain barrier.
Clearance
In a pharmacokinetic study, the apparent oral clearance of carbamazepine was 25 5 mL/min after one dose of carbamazepine and 80 30 mL/min after several doses.
Absorption: Slow and variable, but almost completely absorbed from gastrointestinal tract.
Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2007., p. 703
Patients in whom carbamazepine monotherapy is discontinued for preoperative EEG/video monitoring often display toxicity if their previous maintenance dosage is resumed, even after a few days without carbamazepine. To determine whether this is due to rapid reversibility of autoinduction of carbamazepine metabolism, single-dose studies of carbamazepine pharmacokinetics were performed before and after discontinuation for monitoring in 6 adults receiving carbamazepine monotherapy. The carbamazepine-free period was 5.7 + or - 1.1 days (mean + or - SD). The pharmacokinetic parameters of carbamazepine before and after discontinuation were volume of distribution 1.28 + or - 0.29 versus 1.22 + or - 0.331/kg, elimination half-life (tl/2) 13.7 + or - 1.67 versus 22.2 + or - 2.36 hr (p < 0.001), and clearance 1.54 + or - 0.39 versus 0.92 + or - 0.32 L/kg/day (p = 0.012). Assuming that deinduction is a first-order process, a deinduction tl/2 of 3.84 days was obtained by log linear regression analysis. We showed that after carbamazepine discontinuation half of the enzymatic autoinduction is already lost after 3.84 days, indicating very rapid deinduction. Our results also provide the necessary information to predict clearance and appropriate dosage reduction for carbamazepine at time of reintroduction.
PMID:8112245 Schaffler L et al; Epilepsia 35 (1): 195-8 (1994)
This study was designed to evaluate the usefulness of carbamazepine as a probe in screening for host factor influences on human drug metabolism. Nine healthy nonsmoking volunteers ingested a single oral dose of carbamazepine in doses ranging from 400 to 500 milligrams. Fluorescence polarization immunoassay measurements of carbamazepine concentrations in plasma and plasma ultrafiltrates from 0 to 48 hours after dosing were used to calculate clearance, volume of distribution, and clearance of plasma unbound drug. Blood samples collected 48 hours after dosing gave single sample estimates of carbamazepine clearance which were closest to multiple sample values for clearance. This was also the case for plasma total carbamazepine and plasma unbound carbamazepine. In calculating all single sample estimates of clearance, a value of 1.1 L/kg was used for V and a value of 4.3 L/kg was used to calculate the single sample estimates of clearance of plasma unbound drug. The mean prediction error was less than 5 percent errant for clearance and less than 1 percent errant for clearance of plasma unbound drug when the parameters were calculated from 48 hour concentrations of plasma total carbamazepine or plasma unbound carbamazepine, respectively. ...
PMID:2773507 Bachmann KA et al; Xenobiotica 19 (7): 711-719 (1989)
A fatal overdose of carbamazepine with both timely antemortem and postmortem carbamazepine concentrations /was reported/. Carbamazepine concentrations were 47.7 ug/mL 2 hr antemortem and 53 ug/mL at 9 hr postmortem. The slight rise in drug concentration may reflect continued absorption of the drug in the last 2 hr before death. Postmortem carbamazepine concentrations drawn from a peripheral vessel in this patient appeared to reflect drug concentrations at the time of death.
PMID:11714170 Spiller HA, Carlisle RD; J Forensic Sci 46 (6): 1510-2 (2001)
For more Absorption, Distribution and Excretion (Complete) data for CARBAMAZEPINE (15 total), please visit the HSDB record page.
Carbamazepine is largely metabolized in the liver. CYP3A4 hepatic enzyme is the major enzyme that metabolizes carbamazepine to its active metabolite, carbamazepine-10,11-epoxide, which is further metabolized to its trans-diol form by the enzyme epoxide hydrolase. Other hepatic cytochrome enzymes that contribute to the metabolism of carbamazepine are CYP2C8, CYP3A5, and CYP2B6. Carbamazepine also undergoes hepatic glucuronidation by UGT2B7 enzyme and several other metabolic reactions occur, resulting in the formation of minor hydroxy metabolites and quinone metabolites. Interestingly, carbamazepine induces its own metabolism. This leads to enhanced clearance, reduced half-life, and a reduction in serum levels of carbamazepine.
The pharmacokinetics of a single oral dose of carbamazepine-10,11-epoxide, (100 mg) were compared in 10 patients on chronic monotherapy with lamotrigine, (200-300 mg/day) and in 10 drug-free healthy control subjects. Carbamazepine-10,11-epoxide pharmacokinetic parameters in lamotridge-treated patients were found to be similar to those observed in controls (half-life: 7.2 + or - 1.6 vs 6.1 + or - 0.9 hr; apparent oral clearance: 110.8 + or - 53.1 vs 120.5 + or - 29.9 ml/h/kg; apparent volume of distribution: 1.08 + or 0.37 vs 1.04 + or - 0.25 l/kg respectively; means + or - s.d.). These data indicate that, contrary to previous suggestions, lamotridge has no effect on the metabolic disposition of carbamazepine-10,11-epoxide.
PMID:7698101 Pisani F et al; Epilepsy Res 19 (3): 245-8 (1994)
Placental transfer and metabolism of carbamazepine was studied in a dual recirculating placental cotyledon perfusion system and was also evaluated in 16 pairs of maternal venous and cord blood samples. ... Carbamazepine added into the maternal circulation crosses the placenta in the beginning quicker than antipyrine which is in agreement with the different lipid solubilities of these compounds. Because the transfer rates of antipyrine and carbamazepine were about the same, the mechanism of transfer of carbamazepine is probably similar to that of antipyrine (passive diffusion). No metabolites of carbamazepine could be detected in the perfusate by high-performance liquid chromatography or gas chromatography/mass spectrometry. With the improved HPLC methodology for carbamazepine metabolites, six metabolites were detected in clinical samples, including 10-hydroxy-10,11-dihydro-carbamazepine (10-OH-CBZ), which has been described earlier in only 1 uremic patient. Relative levels of metabolites showed significant individual differences. Carbamazepine crosses perfused placenta rapidly, but this does not contribute to carbamazepine metabolites detected in maternal and fetal circulation.
PMID:7614907 Pienimaki P et al; Epilepsia 36 (3): 241-8 (1995)
The aim of this work was to study the transport across the blood-brain barrier, blood and liver distribution kinetics, metabolic interaction and local liver metabolism of carbamazepine in the rat, using microdialysis with the internal standard technique as in vivo calibration method. Carbamazepine and its major metabolite, carbamazepine-10,11-epoxide, are homogeneously distributed to hippocampus and cerebellum. The ratios of the areas under the concentration-time curve for both brain regions to blood areas under the concentration-time curve were not different from unity for carbamazepine; they were 0.46 + or - 0.08 (hippocampus) and 0.45 + or - 0.05 (cerebellum) for carbamazepine-10,11-epoxide. In addition, the disposition of carbamazepine and carbamazepine-10,11-epoxide in blood and liver, after a single dose of carbamazepine, was studied in control animals and in rats after pretreatment with clomipramine. A 2-fold increase in the blood areas under concentration curve of carbamazepine and a decrease to 33% of the blood areas under concentration curve of carbamazepine-10,11-epoxide in the pretreated group demonstrate the metabolic inhibition of carbamazepine-10,11-epoxide formation by clomipramine. The ratios of the areas under concentration curve carbamazepine-10,11-epoxide to the areas under the concentration curve carbamazepine, as a measure of carbamazepine-10,11-epoxide formation, were not different for blood and liver within the control and the clomipramine-pretreated groups, but the ratios were significantly lower for liver and blood in the clomipramine group compared with the control animals. In addition, carbamazepine was administered locally in the extracellular fluid of the liver via the microdialysis probe. The liver metabolic ratio, expressed as the ratio of the formed carbamazepine-10,11-epoxide concentration to the carbamazepine concentration administered, ranged from 18.2 + or - 1.2% to 19.6 + or - 1.6%.
PMID:7891336 Van Belle K et al; J Pharmacol Exp Ther 272 (3): 1217-22 (1995)
Carbamazepine has known human metabolites that include 2-Hydroxycarbamazepine, 3-Hydroxycarbamazepine, 9-Hydroxycarbamazepine, and Carbamazepine 10,11-epoxide.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
The mean elimination half-life of carbamazepine was 35 to 40 hours after one dose of carbamazepine extended-release formulations. The half-life ranged from 12-17 hours after several doses of carbamazepine. One pharmacokinetic study determined the elimination half-life of carbamazepine to range between 27 to 36.8 hours in healthy volunteers.
Initial single dose: May range from 25 to 65 hours. Chronic dosing: May decrease to 8 to 29 hours (average 12 to 17 hours) because of autoinduciton of metabolism.
Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2007., p. 703
Carbamazepine-10,11-epoxide: 5 to 8 hours. /Carbamazepine-10,11-epoxide/
Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2007., p. 703
Carbamazepine's mechanism of action is not fully elucidated and is widely debated. One major hypothesis is that carbamazepine inhibits sodium channel firing, treating seizure activity. Animal research studies have demonstrated that carbamazepine exerts its effects by lowering polysynaptic nerve response and inhibiting post-tetanic potentiation. In both cats and rats, carbamazepine was shown to decrease pain caused by infraorbital nerve stimulation. A decrease in the action potential in the nucleus ventralis of the thalamus in the brain and inhibition of the lingual mandibular reflex were observed in other studies after carbamazepine use. Carbamazepine causes the above effects by binding to voltage-dependent sodium channels and preventing action potentials, which normally lead to stimulatory effects on nerves. In bipolar disorder, carbamazepine is thought to increase dopamine turnover and increase GABA transmission, treating manic and depressive symptoms. A common issue that has arisen is resistance to this drug in up to 30% of epileptic patients, which may occur to altered metabolism in patients with variant genotypes. A potential therapeutic target to combat carbamazepine resistance has recently been identified as the EPHX1 gene promoter, potentially conferring resistance to carbamazepine through methylation.
Anticonvulsant: Exact mechanism unknown; may act postsynaptically by limiting the ability of neurons to sustain high frequency repetitive firing of action potentials through enhancement of sodium channel inactivation; in addition to altering neuronal excitability, may act presynaptically to block the release of neurotransmitter by blocking presynaptic sodium channels and the firing of action potentials, which in turn decreases synaptic transmission.
Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2007., p. 703
Antineuralgic: Exact mechanism unknown; may involve gamma-aminobutyric acid (GABAB) receptors, which may be linked to calcium channels.
Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2007., p. 703
Antimanic; antipsychotic: Exact mechanism is unknown; may be related to either the anticonvulsant or the antineuralgic effects of carbamazepine, or to tis effects on neurotransmitter modulator systems.
Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2007., p. 703
Antidiuretic: Exact mechanism unknown; may exert a hypothalamic effect on the osmoreceptors mediated via secretion of antidiuretic hormone (ADH), or may have a direct effect on the renal tubule.
Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2007., p. 703
For more Mechanism of Action (Complete) data for CARBAMAZEPINE (8 total), please visit the HSDB record page.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - TABLET;ORAL - 200MG
USFDA APPLICATION NUMBER - 16608
DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 100M...DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 100MG
USFDA APPLICATION NUMBER - 20234
DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 200M...DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 200MG
USFDA APPLICATION NUMBER - 20234
DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 400M...DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 400MG
USFDA APPLICATION NUMBER - 20234
DOSAGE - SOLUTION;INTRAVENOUS - 200MG/20ML (1...DOSAGE - SOLUTION;INTRAVENOUS - 200MG/20ML (10MG/ML)
USFDA APPLICATION NUMBER - 206030
DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 100...DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 100MG
USFDA APPLICATION NUMBER - 20712
DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 200...DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 200MG
USFDA APPLICATION NUMBER - 20712
DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 300...DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 300MG
USFDA APPLICATION NUMBER - 20712
Related Excipient Companies
EUROAPI
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Evonik
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharm-RX Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Faran Shimi Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Boai NKY Pharmaceuticals Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ACG Worldwide
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Aeon Procare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Alcedo Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ashland
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures Pvt Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kima Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lonza Capsugel
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Bold Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nomisma Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Novo Excipients
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qianhao Chemical (Hebei) Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qualicaps
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shijiazhuang Huaxu Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Silverline Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]The Dow Chemical Company
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Valens Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Vasa Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Vertellus
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Zhejiang Huakang Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Fillers, Diluents & Binders
Coating Systems & Additives
Controlled & Modified Release
Thickeners and Stabilizers
Direct Compression
Disintegrants & Superdisintegrants
Granulation
Taste Masking
Film Formers & Plasticizers
Solubilizers
Topical
Parenteral
Lubricants & Glidants
Chewable & Orodispersible Aids
Co-Processed Excipients
Emulsifying Agents
Empty Capsules
Rheology Modifiers
API Stability Enhancers
Coloring Agents
Surfactant & Foaming Agents
Vegetarian Capsules
Dry Powder Inhalation
Soft Gelatin
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
79
PharmaCompass offers a list of Carbamazepine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Carbamazepine manufacturer or Carbamazepine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Carbamazepine manufacturer or Carbamazepine supplier.
PharmaCompass also assists you with knowing the Carbamazepine API Price utilized in the formulation of products. Carbamazepine API Price is not always fixed or binding as the Carbamazepine Price is obtained through a variety of data sources. The Carbamazepine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Carbamazepina manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Carbamazepina, including repackagers and relabelers. The FDA regulates Carbamazepina manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Carbamazepina API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Carbamazepina manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Carbamazepina supplier is an individual or a company that provides Carbamazepina active pharmaceutical ingredient (API) or Carbamazepina finished formulations upon request. The Carbamazepina suppliers may include Carbamazepina API manufacturers, exporters, distributors and traders.
click here to find a list of Carbamazepina suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Carbamazepina DMF (Drug Master File) is a document detailing the whole manufacturing process of Carbamazepina active pharmaceutical ingredient (API) in detail. Different forms of Carbamazepina DMFs exist exist since differing nations have different regulations, such as Carbamazepina USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Carbamazepina DMF submitted to regulatory agencies in the US is known as a USDMF. Carbamazepina USDMF includes data on Carbamazepina's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Carbamazepina USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Carbamazepina suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Carbamazepina Drug Master File in Japan (Carbamazepina JDMF) empowers Carbamazepina API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Carbamazepina JDMF during the approval evaluation for pharmaceutical products. At the time of Carbamazepina JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Carbamazepina suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Carbamazepina Drug Master File in Korea (Carbamazepina KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Carbamazepina. The MFDS reviews the Carbamazepina KDMF as part of the drug registration process and uses the information provided in the Carbamazepina KDMF to evaluate the safety and efficacy of the drug.
After submitting a Carbamazepina KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Carbamazepina API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Carbamazepina suppliers with KDMF on PharmaCompass.
A Carbamazepina CEP of the European Pharmacopoeia monograph is often referred to as a Carbamazepina Certificate of Suitability (COS). The purpose of a Carbamazepina CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Carbamazepina EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Carbamazepina to their clients by showing that a Carbamazepina CEP has been issued for it. The manufacturer submits a Carbamazepina CEP (COS) as part of the market authorization procedure, and it takes on the role of a Carbamazepina CEP holder for the record. Additionally, the data presented in the Carbamazepina CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Carbamazepina DMF.
A Carbamazepina CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Carbamazepina CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Carbamazepina suppliers with CEP (COS) on PharmaCompass.
A Carbamazepina written confirmation (Carbamazepina WC) is an official document issued by a regulatory agency to a Carbamazepina manufacturer, verifying that the manufacturing facility of a Carbamazepina active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Carbamazepina APIs or Carbamazepina finished pharmaceutical products to another nation, regulatory agencies frequently require a Carbamazepina WC (written confirmation) as part of the regulatory process.
click here to find a list of Carbamazepina suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Carbamazepina as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Carbamazepina API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Carbamazepina as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Carbamazepina and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Carbamazepina NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Carbamazepina suppliers with NDC on PharmaCompass.
Carbamazepina Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Carbamazepina GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Carbamazepina GMP manufacturer or Carbamazepina GMP API supplier for your needs.
A Carbamazepina CoA (Certificate of Analysis) is a formal document that attests to Carbamazepina's compliance with Carbamazepina specifications and serves as a tool for batch-level quality control.
Carbamazepina CoA mostly includes findings from lab analyses of a specific batch. For each Carbamazepina CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Carbamazepina may be tested according to a variety of international standards, such as European Pharmacopoeia (Carbamazepina EP), Carbamazepina JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Carbamazepina USP).
